ImetelChat

Thanks Buc!

Kmall, old friend. Here’s the truth. I have always taken you at your word. I have never questioned your bona fides, your sincerity or your commitment to this board. A little volatility in personality makes life interesting. Remember when George Bush filius looked into Putin’s eyes and saw a good per...

Thanks for the kind words and the great comments. I have found the foregoing very reassuring on a number of levels and Ryan even made me laugh. Naturally I along with all of you have been thinking about 2018. A lot of things are different now but I was thinking that the first lemming and the last le...

I will have a definitive answer for you. In about two weeks.

Well, this has certainly been an interesting thread. I will just share a couple of thoughts almost all of which are in the public domaine and the others are personal. First off Dr. Scarlett and company did share that they planned a “gated” spend. The company financial slide showed a skyward increase...

I have a few more thoughts to share but won’t get to it until later tonight

Kmall, let’s start with the lymphoma study at MD Anderson. To better understand the history of the carrot, all one has to do is substitute the words Lane for Iyer and AML for lymphoma. Four years ago Dr. Scarlett held a conference that headlined Dr. Lane and his AML research. Very impressive mouse r...

I could not help but notice that some regular and valued posters are a little edgy after ASH given the absence of a major PR program by Geron post presentations. The fact is, the clinical data to date, has been milked (with the exception of the new data on Luspatercept failures which was encouraging...

You both make very valid points. There have been many false starts over the years. Many. Starting with a 2017 time line for a marketable drug. It’s all moot since we stayed in and followed closely and suffered many disappointments together. In a little over two weeks we will know if the emperor is a...

“ This leader will manage the data lifecycle from strategy, acquisition, management, and governance in addition to identifying, driving prioritizing, and monitoring the successful development of a US Commercial Technology Ecosystem for all future Geron Hematology / Oncology portfolio products.”

Kmall, thanks to your own efforts, many who read and contribute to this board have found a great deal of reassurance in reviewing the now 100 or so names and positions of highly qualified, experienced people in the pharma industry. I know I have. There is a lot of talent and overlap of skill sets, n...

Hat tip to Hunt. Very reassuring and valuable.

Aron shared that Olivia and team are covering until her return. Any concerns can be addressed via IR. Personally I am delighted that she has the confidence in herself as well as Geron having the confidence her to show support associated with important life events, especially those associated with lo...

https://ashpublications.org/hematology/ ... lofibrosis

Let’s hope that changes soon.

More postions posted on "Careers site" Geron home page.

Because we can't. If you are truly a "doctor real" you would know the FDA has strict naming requirements and Imetelstat is a generic name. But keep trying, you might come up with something great!! But we could call it "Imetelchat".

More on this. When Geron talked about Imetelstat having a highly differentiated profile from the competition, I attributed this to anticipated improved TI VAF etc, all the things we have talked about. But after reading Dr. Heyrman’s article and seeing the surprisingly lukewarm effect of luspatercept...

From the clinical trial site: Part 2 (Main Study): Assessment of Functional Assessment of Cancer Therapy-Anemia-Related Effects (FACT-An) [ Time Frame: During study (approximately 2 years) ] The Functional Assessment of Cancer Therapy Anemia (FACT-An), is included in order to provide an assessment o...